NCCN Guidelines for Patients
Colon Cancer, Version 1.2014
7.4 FOLFOXIRI pathways
Chart 7.4 The FOLFOXIRI pathways
FOLFOXIRI. FOLFIRI may be taken with or without
bevacizumab. You may have worse side effects with
FOLFOXIRI than if you were taking FOXFIRI. Thus,
this pathway is only recommended if the tumor is
likely to shrink enough so surgery would be possible.
If the cancer progresses, regorafenib is an option.
genes are normal, you may also take
panitumumab or cetuximab with irinotecan. If you’re
unable to take irinotecan, you may take panitumumab
or cetuximab alone.
If these regimens fail, treatment options include
regorafenib, clinical trials, and best supportive care.
Supportive care treats the symptoms of cancer but
not the cancer itself.
FOLFOXIRI + bevacizumab,
– Irinotecan + panitumumab,
– Irinotecan + cetuximab, or
– Panitumumab or cetuximab if unable to
Clinical trial, or
Best supportive care
Chart 7.4 FOLFOXIRI pathways